Vir Biotechnology Inc

VIR

Company Profile

  • Business description

    Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

  • Contact

    1800 Owens Street
    Suite 900
    San FranciscoCA94158
    USA

    T: +1 415 906-4324

    E: [email protected]

    https://www.vir.bio

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    408

Stocks News & Analysis

stocks

Production increase on track for ASX hydrocarbon producer

Our view after lower earnings.
stocks

Market pricing in further upside in overvalued ASX bank

We view the shares are materially overvalued.
stocks

Chart of the Week: Lithium is rebounding on rising demand

The mining sector is significantly overvalued on average but select value to be found.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,316.6023.80-0.25%
CAC 408,429.030.000.00%
DAX 4025,278.21279.811.12%
Dow JONES (US)49,662.66129.470.26%
FTSE 10010,686.18130.011.23%
HKSE26,705.94138.820.52%
NASDAQ22,753.63175.250.78%
Nikkei 22557,467.83323.990.57%
NZX 50 Index13,444.20197.181.49%
S&P 5006,881.3138.090.56%
S&P/ASX 2009,086.2024.30-0.27%
SSE Composite Index4,082.0751.95-1.26%

Market Movers